Boosting Long-Lasting Protection Against Lung Viruses and Fungi
Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens
This project is developing new vaccine ingredients to help your body build strong, lasting protection against common lung infections like the flu and certain fungi.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11083562 on NIH RePORTER |
What this research studies
Many lung infections caused by viruses and fungi are a big problem, and we don't have good vaccines for most of them. This work focuses on creating better vaccine ingredients, called adjuvants, to help your immune system remember these invaders for a long time. Researchers are particularly interested in training specific immune cells, called T cells, to stay in your lungs and protect you. They are combining different adjuvants to see if this mix can create a stronger and more durable immune response against these tough infections.
Who could benefit from this research
Good fit: This foundational work is not directly recruiting patients but aims to benefit anyone susceptible to severe respiratory viral and fungal infections in the future.
Not a fit: Patients seeking immediate treatment for current infections would not directly benefit from this early-stage vaccine development.
Why it matters
Potential benefit: If successful, this work could lead to new vaccines that offer long-lasting protection against a wider range of severe respiratory viral and fungal infections.
How similar studies have performed: While the concept of adjuvants is established, this specific combination and its ability to program durable, multifaceted T-cell immunity against both viruses and fungi represents a novel approach.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Suresh, Marulasiddappa — University of Wisconsin-Madison
- Study coordinator: Suresh, Marulasiddappa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.